Hey there

CCO Expert Recap

Focus on Investigational HCV Agents

Source: CCO Independent Conference Coverage of the 2008 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Focus on Investigational HCV Agents

Faculty:

Nezam H. Afdhal, MD, FRCPI

CME CREDIT INFORMATION

Release Date: 08/20/08

Expiration Date: 08/19/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data from the PROVE studies of telaprevir and peginterferon/ribavirin for the treatment of genotype 1 hepatitis C virus–infected patients
Discuss the safety and efficacy of boceprevir for the treatment of treatment-naive and nonresponder patients with genotype 1 chronic hepatitis C
Recount data on novel polymerase inhibitors for the treatment of chronic hepatitis C
Describe the importance of ribavirin in treating chronic hepatitis C and the role of ribavirin analogues
Discuss anti–hepatitis C virus agents with novel mechanisms of action

CCO Expert Recaps combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.